Moreover, apatinib was demonstrated to enhance the sensitivity of osteosarcoma cells to doxorubicin and inhibited the doxorubicin-induced stemness phenotype through STAT3/Sox2 pathway inactivation (32). Here, SOX2 is linked to osteosarcoma.